Hong Kong · Delayed Price · Currency is HKD Sinopharm Group Statistics
Total Valuation
Sinopharm Group has a market cap or net worth of HKD 54.64 billion. The enterprise value is 157.35 billion.
| Market Cap | 54.64B |
| Enterprise Value | 157.35B |
Important Dates
The last earnings date was Friday, April 24, 2026.
| Earnings Date | Apr 24, 2026 |
| Ex-Dividend Date | Jun 23, 2026 |
Share Statistics
Sinopharm Group has 3.12 billion shares outstanding. The number of shares has increased by 0.24% in one year.
| Current Share Class | 1.34B |
| Shares Outstanding | 3.12B |
| Shares Change (YoY) | +0.24% |
| Shares Change (QoQ) | +0.80% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 29.14% |
| Float | 1.34B |
Valuation Ratios
The trailing PE ratio is 6.79 and the forward PE ratio is 6.03. Sinopharm Group's PEG ratio is 1.50.
| PE Ratio | 6.79 |
| Forward PE | 6.03 |
| PS Ratio | 0.08 |
| PB Ratio | 0.35 |
| P/TBV Ratio | 0.63 |
| P/FCF Ratio | 3.27 |
| P/OCF Ratio | 2.96 |
| PEG Ratio | 1.50 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.18, with an EV/FCF ratio of 9.41.
| EV / Earnings | 19.46 |
| EV / Sales | 0.24 |
| EV / EBITDA | 6.18 |
| EV / EBIT | 7.54 |
| EV / FCF | 9.41 |
Financial Position
The company has a current ratio of 1.40, with a Debt / Equity ratio of 0.56.
| Current Ratio | 1.40 |
| Quick Ratio | 1.10 |
| Debt / Equity | 0.56 |
| Debt / EBITDA | 3.58 |
| Debt / FCF | 5.15 |
| Interest Coverage | 7.69 |
Financial Efficiency
Return on equity (ROE) is 8.11% and return on invested capital (ROIC) is 7.59%.
| Return on Equity (ROE) | 8.11% |
| Return on Assets (ROA) | 2.63% |
| Return on Invested Capital (ROIC) | 7.59% |
| Return on Capital Employed (ROCE) | 11.73% |
| Weighted Average Cost of Capital (WACC) | 4.00% |
| Revenue Per Employee | 6.88M |
| Profits Per Employee | 85,176 |
| Employee Count | 94,910 |
| Asset Turnover | 1.41 |
| Inventory Turnover | 8.03 |
Taxes
In the past 12 months, Sinopharm Group has paid 4.53 billion in taxes.
| Income Tax | 4.53B |
| Effective Tax Rate | 27.04% |
Stock Price Statistics
The stock price has decreased by -5.15% in the last 52 weeks. The beta is 0.48, so Sinopharm Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -5.15% |
| 50-Day Moving Average | 19.93 |
| 200-Day Moving Average | 19.82 |
| Relative Strength Index (RSI) | 24.27 |
| Average Volume (20 Days) | 5,960,990 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sinopharm Group had revenue of HKD 652.76 billion and earned 8.08 billion in profits. Earnings per share was 2.58.
| Revenue | 652.76B |
| Gross Profit | 46.78B |
| Operating Income | 19.48B |
| Pretax Income | 16.77B |
| Net Income | 8.08B |
| EBITDA | 21.76B |
| EBIT | 19.48B |
| Earnings Per Share (EPS) | 2.58 |
Balance Sheet
The company has 41.34 billion in cash and 86.11 billion in debt, with a net cash position of -44.77 billion or -14.35 per share.
| Cash & Cash Equivalents | 41.34B |
| Total Debt | 86.11B |
| Net Cash | -44.77B |
| Net Cash Per Share | -14.35 |
| Equity (Book Value) | 155.14B |
| Book Value Per Share | 31.15 |
| Working Capital | 115.24B |
Cash Flow
In the last 12 months, operating cash flow was 18.47 billion and capital expenditures -1.74 billion, giving a free cash flow of 16.73 billion.
| Operating Cash Flow | 18.47B |
| Capital Expenditures | -1.74B |
| Depreciation & Amortization | 2.31B |
| Net Borrowing | -21.34B |
| Free Cash Flow | 16.73B |
| FCF Per Share | 5.36 |
Margins
Gross margin is 7.17%, with operating and profit margins of 2.98% and 1.24%.
| Gross Margin | 7.17% |
| Operating Margin | 2.98% |
| Pretax Margin | 2.57% |
| Profit Margin | 1.24% |
| EBITDA Margin | 3.33% |
| EBIT Margin | 2.98% |
| FCF Margin | 2.56% |
Dividends & Yields
This stock pays an annual dividend of 0.80, which amounts to a dividend yield of 4.35%.
| Dividend Per Share | 0.80 |
| Dividend Yield | 4.35% |
| Dividend Growth (YoY) | -22.70% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 28.21% |
| Buyback Yield | -0.24% |
| Shareholder Yield | 4.11% |
| Earnings Yield | 14.79% |
| FCF Yield | 30.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sinopharm Group has an Altman Z-Score of 2.22 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.22 |
| Piotroski F-Score | 6 |